Transanal total mesorectal excision for low and middle rectal cancer: time for audit?

Since the introduction of transanal total mesorectal excision (TaTME) [1] for the treatment of rectal cancer, expert centers have reported very encouraging results. It appears that TaTME is becoming the new standard for surgical treatment of low and mid rectal cancer. Supposedly, TaTME provides bett...

Full description

Saved in:
Bibliographic Details
Published inTechniques in coloproctology Vol. 23; no. 8; pp. 703 - 705
Main Authors Aubert, M., Mege, D., Panis, Y.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.08.2019
Springer Nature B.V
Subjects
Abdominal Surgery
Cancer surgery
Colorectal cancer
Colorectal Surgery
Editorial
Female
Gastroenterology
Humans
Male
Medical Audit
Medicine
Medicine & Public Health
Oncology
Proctectomy - methods
Proctectomy - trends
Proctology
Rectal Neoplasms - surgery
Surgery
Transanal Endoscopic Surgery - methods
Transanal Endoscopic Surgery - trends
Online AccessGet full text

Cover

More Information
Summary:Since the introduction of transanal total mesorectal excision (TaTME) [1] for the treatment of rectal cancer, expert centers have reported very encouraging results. It appears that TaTME is becoming the new standard for surgical treatment of low and mid rectal cancer. Supposedly, TaTME provides better visualization of the area of the mid-rectum (so called “the rectal no man’s land”), especially in the obese male patient, with narrow pelvis and/or bulky tumor, which allows not only better nerve preservation but also better oncological resection with a lower rate of R1 resection than standard laparoscopic TME from above. Some studies described better functional outcomes, due to the better preservation of the external sphincter and nerves.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1123-6337
1128-045X
DOI:10.1007/s10151-019-02075-x